Features of the “Thrombodynamics” test in patients with cancer

Introduction: Thromboembolic complications are one of the leading causes of mortality among cancer patients, significantly worsening their clinical condition and prognosis. Effective diagnostic methods for hypercoagulation and prevention of thromboembolic complications are essential for oncological patients. The “Thrombodynamics” test is an integrative tool that allows for a more precise assessment of the fibrin clot formation process in conditions that closely mimic physiological conditions. Aim: To evaluate the features of hemostasis in patients with cancer using the “Thrombodynamics” test and to identify potential differences in thrombogenic activity depending on the tumor localization. Materials and methods: The study included 100 patients, aged (65 ± 10.6) years, with 75 patients forming the main group (patients with histologically confirmed cancer) and 25 patients forming the control group (healthy individuals). Patients in both groups were matched by gender, age, and comorbidities. The “Thrombodynamics” test was performed according to the standard protocol using the “Thrombodynamics Recorder T-2” system (SDL RT T-2, GemaKor, Moscow, Russia). Results: The results of the study showed that patients with malignant neoplasms have pronounced hypercoagulability, which is confirmed by an increase in the growth rate of the fibrin clot, the initial growth rate and the clot size compared to the control group. Although the differences in the clot growth delay time were insignificant, all other parameters in patients with malignant neoplasms exceeded the reference values, indicating increased thrombogenic activity. И: The Thrombodynamics test shows hypercoagulation in patients with cancer. Further studies are needed to better understand the mechanisms of hypercoagulability in various types of cancer and optimize the methods of TEC prevention in these patients.